首页> 中文期刊>中国医药导报 >D-二聚体纤维蛋白原抗凝血酶Ⅲ在早期冠心病诊疗中的价值

D-二聚体纤维蛋白原抗凝血酶Ⅲ在早期冠心病诊疗中的价值

     

摘要

目的 探讨D-二聚体、纤维蛋白原、抗凝血酶Ⅲ在早期冠心病诊疗中的临床价值.方法选择2011年1月~2012年7月我院收治的早期冠心病患者128例为观察组,选择本院同期健康体检人员130例为对照组,分别检测两组人员的血脂水平、凝血系统指标、血浆指标.结果血脂检测中,观察组总胆固醇、三酰甘油、低密度脂蛋白均明显高于对照组,观察组高密度脂蛋白明显低于对照组,差异均有统计学意义(均P < 0.05).凝血系统指标检测中,观察组凝血酶原时间、活化部分凝血活酶时间均明显小于对照组,差异均有统计学意义(均P < 0.05).血浆指标检测中,观察组D-二聚体、纤维蛋白原均明显高于对照组,观察组抗凝血酶Ⅲ明显低于对照组,差异均有统计学意义(均P < 0.05).结论早期冠心病患者存在血脂、D-二聚体、纤维蛋白原、抗凝血酶Ⅲ的异常表达,及早检测有助于早期冠心病的诊断和病情判断,值得临床推广使用.%Objective To investigate the clinical value on D-two dimer,fibrinogen,antithrombin Ⅲ in the diagnosis and treatment of early coronary heart disease. Methods 128 patients with early coronary heart disease were selected in our hospital from January 2011 to July 2012 as the observation group. 130 health physical examination personnel were selected in our hospital in the same period as the control group. The lipid levels,coagulation system indexes,plasma parameters were examined between the two groups. Results In the detection of lipid levels,total cholesterol,triglyceride,low density lipoprotein in the observation group were significantly higher than those in the control group,high density lipoprotein in the observation group was significantly lower than that in the control group,the differences were statistically significant (P < 0.05). In the detection of coagulation system indexes,prothrombin time,activated partial thromboplastin time in the observation group were significantly smaller than those in the control group,the differences were statistically significant (P < 0.05). In the detection of plasma parameters,D- two dimer,fibrinogen in the observation group were significantly higher than those in the control group,Antithrombin Ⅲ in the observation group was significantly lower than that in the control group,the differences were statistically significant (P < 0.05). Conclusion Patients with early coronary heart disease have abnormal expression of lipids,D- two dimer,fibrinogen,antithrombin Ⅲ. Early detection contribute to early diagnosis of coronary heart disease and the severity are worthy of clinical use.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号